June 2026 - Page 8 of 9

America’s Commercial Lunar Economy Just Got Its Most Important Infrastructure Deal Yet

Posted on June 2, 2026June 2, 2026 by [email protected]

The race to build permanent infrastructure on the Moon has a new and more serious player. Voyager Technologies (NYSE: VOYG), a Denver-based defense technology and space solutions company, announced Tuesday it has signed a definitive agreement to acquire Astrobotic Technology, the Pittsburgh-based commercial lunar logistics and robotics company, for up to approximately $300 million in a combination of cash and stock. The deal is expected to close by early July 2026, subject to customary regulatory approvals.

For a company that has been quietly assembling a full-stack lunar infrastructure portfolio, the Astrobotic acquisition is the piece that makes the entire architecture operational.

What Astrobotic Brings to the Table

Founded in 2007 as a Carnegie Mellon University spinout, Astrobotic has spent nearly two decades building the hardware, software, and operational expertise required to deliver payloads to the lunar surface reliably and repeatably. The company has secured more than $600 million in NASA and Department of Defense contracts and holds the distinction of having launched America’s first commercial lunar lander. Its core product portfolio includes the Peregrine lander for smaller payload missions, the Griffin lander for larger surface delivery operations, and LunaGrid, a solar power distribution system designed to provide sustained electricity on the lunar surface.

That last element matters as much as the landers. A permanent human presence on the Moon requires more than transportation. It requires power infrastructure that can sustain life, operations, and scientific activity across lunar day-night cycles that last approximately two Earth weeks each. LunaGrid is purpose-built for exactly that requirement.

Astrobotic’s Moon Base headquarters in Pittsburgh will become the center of Voyager’s lunar program following close, with the company’s facility in Mojave also continuing operations.

The Full Stack Voyager Is Building

The Astrobotic acquisition does not stand alone. Voyager has been executing a deliberate vertical integration strategy across the lunar infrastructure stack, and this deal slots directly into that roadmap. The combined company will now span lunar mission management, communications and propulsion, surface delivery through Peregrine and Griffin, surface power through LunaGrid, long-duration habitation through its prior strategic investment in Max Space’s expandable habitat architecture, dust mitigation through Voyager’s proprietary clear-dust repellent coating technology, and in-situ resource production.

That is a comprehensive end-to-end lunar capability assembled through targeted acquisitions rather than organic development alone. The strategic efficiency of that approach is notable for a company operating in the small cap space.

The acquisition directly supports NASA’s Artemis program and Administrator Jared Isaacman’s stated commitment to establishing a permanent American presence on the Moon by 2028. Astrobotic’s Griffin Mission One, recently designated NASA’s Moon Base II mission, is proceeding on schedule and will transition fully under Voyager at close.

Why This Deal Matters for Small Cap Space Investors

The commercial lunar economy is not a distant concept. It is a funded, contracted, timeline-driven government priority with hundreds of millions of dollars already flowing to companies like Astrobotic. What has been missing is the kind of vertically integrated commercial operator capable of managing every layer of a sustained lunar presence. Voyager is systematically becoming that operator.

With SpaceX’s June 12 IPO approaching at a targeted $1.75 trillion valuation and the broader space infrastructure sector attracting record institutional attention, consolidation among smaller space technology companies is accelerating. Voyager’s acquisition of Astrobotic is precisely the kind of strategic move that positions a small cap defense and space company for the contracts, partnerships, and government relationships that will define the commercial lunar economy over the next decade.

Power Metallic Mines Inc. (PNPNF) – Advancing Lion Resource Growth and Expanding District Exploration

Posted on June 2, 2026June 2, 2026 by [email protected]

Tuesday, June 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Recent Drill Results. Power Metallic reported strong drill results from the Lion deposit, including high-grade near-surface copper intercepts, while metallurgical testing demonstrated excellent recoveries from lower-grade material. The results support resource growth potential and enhance confidence ahead of the upcoming NI 43-101 Mineral Resource Estimate (MRE) expected in late July and a Preliminary Economic Assessment (PEA) in December 2026.

Summer Exploration and Drilling Program. Power Metallic has expanded its summer exploration program at the Nisk Project with advanced geophysical surveys and more than 30,000 meters of planned drilling. The program is designed to identify extensions of known mineralization and generate new discovery targets across the company’s Nisk land package while supporting future resource growth.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Summit Midstream Corp (SMC) – Inaugural Stock Repurchase Program

Posted on June 2, 2026June 2, 2026 by [email protected]

Tuesday, June 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Stock Repurchase Authorization. Summit Midstream Corporation announced that its Board of Directors has authorized the company’s first stock repurchase program, allowing for the repurchase of up to $35 million of outstanding common stock. As of May 8, shares outstanding were 20.3 million, including 13.8 million common shares and 6.5 million Class B common shares.

Terms of the Program. Summit may repurchase shares through open market transactions, privately negotiated purchases, block trades, or other methods permitted under applicable securities laws. Repurchase activity will depend on market conditions, share price, debt covenant compliance, and other factors. The program has no expiration date, does not require the company to buy back any specific number of shares, and may be suspended or terminated at any time.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

MAIA Biotechnology (MAIA) – Phase 3 THIO-104 Trial Design Presented At ASCO

Posted on June 2, 2026June 2, 2026 by [email protected]

Tuesday, June 02, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 THIO-104 Design Is Consistent With Expectations. MAIA presented a poster on May 31, 2026, at the Annual ASCO (American Society of Clinical Oncology) Meeting. The poster detailed the design of its ongoing Phase 3 THIO-104 trial that tests ateganosine (aka THIO) in combination with the checkpoint inhibitor cemiplimab as a third-line treatment for patients with non-small cell lung cancer (NSCLC) who have become resistant to CPI treatment and chemotherapy.

Trial Design Is Consistent With Results From Phase 2 THIO-101 Trial. The patient population, selected dose, and combination regimen with Ateganosine 180mg and cemiplimab (Libtayo, from Regeneron) are the same as those in the Phase 2 THIO-101 study. At last analysis as of June 30, 2025, this regimen showed a median observed Overall Survival (OS) of 17.8 months, compared with published studies reporting an OS of 5.8 months.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

V2X (VVX) – Raising Price Target

Posted on June 2, 2026June 2, 2026 by [email protected]

Tuesday, June 02, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Raising Price Target. With VVX share moving north of our $72 price target, we are increasing our target to $92 while maintaining our Outperform rating. At our new price target, VVX shares would trade at 0.8x our projected 2026 revenue, 11x our projected 2026 adjusted EBITDA, and 15.5x our projected 2026 adjusted EPS. These multiples are in line with VVX’s key competitors. VX shares are up approximately 52% y-t-d, versus an 11% rise for the S&P 500.

Overhang Removed. With American Industrial Partners’ May 2026 sale of approximately 2 million VVX shares, the firm is essentially out of V2X shares, completing a two-year process as AIP liquidated its 61%+ ownership stake in V2X acquired in the merger of Vectrus and Vertex, removing an ongoing overhang of stock, in our view. An entity affiliated with Vertex Aerospace did, however, continue to beneficially own 375,420 shares, or approximately 1.2%, of V2X’s outstanding common stock following the most recent share sale.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Greenwich LifeSciences, Inc. (GLSI) – Additional Phase 3 FLAMINGO-01 Data Presented At ASCO Meeting

Posted on June 2, 2026June 2, 2026 by [email protected]

Tuesday, June 02, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Additional Data Presented At ASCO. Greenwich LifeSciences presented an abstract and poster at the ASCO Annual Meeting. The data assessed non-HLA-A*02 patients in the open-label arm after six monthly doses of GLA-100. The data show statistically significant injection site reaction (ISR) and immune response at baseline, with increases over time.

Patients Were Evaluated After Initial Immune Stimulation. Patients received the Primary Immunization Series (PIS), consisting of six vaccinations over the first six months of the trial. The fourth, fifth, and sixth vaccinations showed a significant increase in the percentage of patients showing an ISR compared to baseline. Of the 247 patients enrolled, 208 had both baseline vaccination and assessments at 4, 5, or 6 months.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Aurania Resources (AUIAF) – First Tranche of Private Placement Closed

Posted on June 2, 2026June 2, 2026 by [email protected]

Tuesday, June 02, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Private Placement Financing. Aurania Resources Ltd. closed the first tranche of its previously announced non-brokered private placement, raising C$678,263.76 through the issuance of 3,768,132 units at C$0.18 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at a price of C$0.35 per share for a period of 24 months following the close of the first tranche. The financing is part of a larger offering of up to 8,333,333 units that could generate total gross proceeds of up to approximately C$1.5 million. Dr. Keith Barron, Aurania’s Chief Executive Officer and President, participated in the financing by acquiring 1,666,666 units.

Use of Proceeds. The net proceeds will be used to fund exploration at the Thor’s Valley epithermal gold project in Iceland, support the Balangero nickel-cobalt tailings retreatment project in Italy, and fund general working capital. In May, Aurania closed its option agreement with St-Georges Eco-Mining Corp (CSE: SX) and its wholly owned subsidiary, Iceland Resources, to work collaboratively to define and execute a phased exploration program at the Thor’s Valley gold project to advance the project toward initial modern resource definition.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Anthropic Just Filed for an IPO at $965 Billion. The AI Capital Cycle Has Entered a New Phase

Posted on June 2, 2026June 2, 2026 by [email protected]

The artificial intelligence industry’s march toward public markets just crossed a threshold that Wall Street has been watching closely for months. Anthropic, the San Francisco-based AI company behind the Claude family of large language models, confirmed Monday it has submitted a confidential draft S-1 registration statement to the Securities and Exchange Commission — the first formal legal step toward an initial public offering.

The filing contains no share count, no price range, and no confirmed listing date. Under the confidential process, full financial disclosures remain private until the SEC completes its review, at which point Anthropic will decide whether to proceed based on market conditions. A public debut as early as Fall 2026 is widely expected.

What is known is the valuation at which Anthropic is entering this process. Just days before the filing, the company closed a $65 billion Series H funding round co-led by Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, and D1 Capital Partners, pushing its post-money valuation to approximately $965 billion. That figure places Anthropic ahead of rival OpenAI in private market valuation and positions it at the front of the most consequential IPO pipeline in the history of the technology industry.

The Company Behind the Filing

Anthropic was founded in 2021 by Dario Amodei, Daniela Amodei, and several colleagues who departed OpenAI. The company has built its business on the Claude model family, which spans consumer, enterprise, and frontier AI applications, and has established major compute agreements with Amazon, Google, and Broadcom. Claude is available across AWS, Google Cloud, and Microsoft Azure, giving the company distribution through the three largest cloud platforms simultaneously. The company’s CFO described the latest funding round as support to serve the demand for Claude while expanding research, compute capacity, and product partnerships.

The Broader IPO Context

Anthropic’s filing lands inside what is shaping up to be the most concentrated AI IPO season in market history. Cerebras Systems debuted on Nasdaq in May, surging nearly 90% on its first day of trading in the largest US tech IPO since Uber in 2019. SpaceX’s roadshow begins Thursday with the June 12 Nasdaq listing targeting a $1.75 trillion valuation and a $75 billion raise. OpenAI is expected to follow Anthropic to the SEC with its own filing in the weeks ahead.

The cumulative implied valuation of these four AI companies alone approaches $4 trillion. That number represents an entirely new category of public market listing, and its effect on sentiment, capital allocation, and sector multiples across the AI ecosystem is already being felt.

What It Means for Smaller AI Companies

For investors in the sub-$2 billion AI space, the Anthropic filing matters for a specific reason. Cerebras and Nvidia represent the hardware and infrastructure layer of AI. Anthropic and OpenAI represent the model and software layer. When both layers of the AI stack are simultaneously achieving historic public market valuations, the effect on smaller companies operating across either layer is historically consistent: institutional capital broadens its reach, multiples expand across the sector, and the companies that were already building real products in the space benefit from the rising tide.

The IPO window that cracked open with Cerebras in May is now wide open. Anthropic just made sure of it.

Quantum Computing Inc. Spent $110 Million to Become Vertically Integrated

Posted on June 2, 2026June 2, 2026 by [email protected]

When Quantum Computing Inc. (Nasdaq: QUBT) announced in December 2025 that it would acquire Luminar Semiconductor for $110 million in cash from a bankrupt parent company, the market’s immediate reaction was a 7% single-day drop. The deal looked expensive, the target was emerging from a Chapter 11 process, and questions about whether a microcap quantum computing company could absorb an acquisition of that scale were entirely legitimate.

Four months later, the first full quarter of post-acquisition results are on the table, and the numbers tell a different story than the initial skepticism suggested.

What QUBT Actually Bought

Luminar Semiconductor was a wholly owned subsidiary of Luminar Technologies, the lidar company that filed for Chapter 11 bankruptcy concurrently with the sale announcement. Critically, Luminar Semiconductor itself was not a debtor in the bankruptcy. It was operating normally as a subsidiary and continued doing so through the court-supervised Section 363 sale process, which QUBT won as the stalking horse bidder. The deal closed February 2, 2026.

What transferred to QUBT was a portfolio of established photonic technology businesses including Black Forest Engineering, Optogration, Freedom Photonics, and EM4 — collectively representing a mature set of capabilities in lasers, photodetectors, optical packaging, and manufacturing. These are not experimental technologies. They have existing commercial customers in defense, sensing, and optical communications, generating real revenue before a single quantum application is layered on top.

The strategic logic was vertical integration. QUBT operates a thin-film lithium niobate foundry in Tempe, Arizona, producing photonic chips that form the hardware foundation for its quantum systems. Luminar Semiconductor’s components are direct building blocks on that technology roadmap. By acquiring the supplier rather than remaining dependent on it, QUBT gained control of its supply chain, expanded its engineering depth, and added an established revenue base in a single transaction.

The Post-Acquisition Numbers

Q1 2026 revenue came in at $3.7 million, surging from near zero in the prior year period and significantly outpacing analyst consensus estimates. The net loss narrowed to $4.1 million, or $0.02 per share, better than expected. Total assets at March 31 stood at approximately $1.6 billion, supported by a cash position of roughly $1.4 billion — a substantial liquidity cushion for a company of this size and stage. The stock gained 7% on earnings day and has advanced nearly 30% over the past month. Six analysts currently carry Buy ratings on the stock with an average price target of $17.83, implying approximately 49% upside from current levels.

The Broader Context

The acquisition does not exist in isolation. Two weeks ago, the Trump administration announced $2 billion in equity investments across nine domestic quantum computing companies under the CHIPS and Science Act framework — a commitment that signals the federal government views quantum computing as a strategic national priority rather than a speculative technology bet. While QUBT was not among the direct recipients in that announcement, the government validation of the sector broadly benefits every company operating in the quantum computing ecosystem.

QUBT’s vertical integration strategy positions it as one of the few quantum companies attempting to control both the photonic hardware and the quantum application stack simultaneously, a differentiated approach in a sector where most competitors rely on third-party component suppliers.

The Risk Profile

The honest assessment includes the other side of the ledger. Earnings are projected to decline significantly on a per-share basis as the company scales operations and absorbs integration costs. The stock trades at extreme price-to-sales multiples relative to current revenue. Cash burn remains a structural feature of the business at this stage, and dilution risk through future capital raises is a real variable. These are not edge cases — they are the central risks any investor in early-stage quantum computing needs to underwrite.

What has changed since the December acquisition announcement is that the revenue baseline is now measurably higher, the integration appears to be proceeding on track, and the government has put $2 billion of validation behind the sector QUBT is building into.

Release – GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat Readiness

Posted on June 1, 2026June 1, 2026 by [email protected]

Research News and Market Data on GOVX

Largest FIFA Tournament in History Expected to Draw 6.5 Million Attendees Across North America and More Than 1.2 Million International Visitors to U.S. Host Cities Amid Growing Concerns Regarding Mpox, Ebola, Hantavirus, Measles, and Other Emerging Infectious Disease Threats

ATLANTA, GA – June 1, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today welcomed the upcoming FIFA World Cup 2026 and highlighted the importance of public health readiness, healthcare capacity, and biodefense capabilities as North America prepares to host the largest sporting event in history.

According to a recent economic impact analysis conducted by Oxford Economics and Tourism Economics, FIFA World Cup 2026 is expected to attract approximately 6.5 million attendees across the United States, Canada, and Mexico, including more than 1.2 million international visitors traveling to U.S. host cities alone. For public health authorities, healthcare systems, emergency management agencies, and national security planners, the tournament represents a real-world test of disease surveillance, healthcare capacity, emergency response coordination, vaccine availability, and critical public health infrastructure at a scale rarely encountered outside of a global crisis.

The event arrives amid a period of increasing infectious disease activity marked by ongoing Clade I mpox transmission, the escalating Bundibugyo Ebola outbreak in Central Africa, renewed concern surrounding zoonotic pathogens such as hantavirus and avian influenza, and growing measles outbreaks in multiple regions. Together, these developments reinforce a broader reality: biological threats are becoming more global, more interconnected, and increasingly simultaneous.

“FIFA 2026 represents more than a sporting event. It is a large-scale operational challenge occurring in an era of persistent biological risk,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “When millions of people move across borders, transportation networks, and densely populated urban environments over a compressed period of time, health security becomes an operational necessity. The ability to detect, monitor, and respond rapidly to emerging infectious disease threats will be as important as the infrastructure supporting the tournament itself.”

Mass gatherings do not create outbreaks. However, they can amplify the operational consequences of existing vulnerabilities. Millions of visitors moving through airports, public transportation systems, hotels, entertainment venues, and urban centers create conditions that test disease surveillance systems, laboratory capacity, healthcare surge capabilities, public communication networks, and cross-jurisdictional coordination.

Recent outbreaks have reinforced the reality that governments can no longer focus on a single pathogen at a time. The continued spread of mpox beyond historically endemic regions, the emergence of more virulent viral strains, and the ongoing Bundibugyo Ebola outbreak, which currently lacks a broadly licensed vaccine specifically approved for widespread deployment, underscore the need for flexible response capabilities able to address multiple evolving threats simultaneously.

“The central challenge is no longer responding to a single outbreak,” continued Dodd. “Governments and health systems increasingly require the ability to manage multiple biological threats at once. Health security today means more than surveillance. It requires manufacturing capacity, supply-chain diversification, stockpile availability, operational coordination, and the ability to rapidly deploy effective countermeasures when and where they are needed.”

GeoVax believes several priorities warrant increased attention as FIFA 2026 approaches:

Expanding domestic vaccine manufacturing capacity
Diversifying critical medical countermeasure supply chains
Enhancing disease surveillance and rapid-response capabilities
Supporting adaptable vaccine platform technologies
Strengthening public-private health security partnerships
Improving stockpile management and deployment logistics

A New Era of Biological Risk

The World Cup does not create vulnerabilities. It has the potential to expose them.

Recent mpox outbreaks demonstrated how rapidly demand for vaccines and medical countermeasures can outpace available supply. The Bundibugyo Ebola outbreak has highlighted continuing gaps in available tools for emerging pathogen variants. At the same time, concerns regarding zoonotic spillover events, international mobility, and supply-chain concentration have reinforced the importance of scalable manufacturing capacity, diversified sourcing, flexible vaccine technologies, and geographically distributed biodefense infrastructure.

The ongoing mpox environment has also highlighted the strategic importance of poxvirus vaccine availability. Today, global supply of MVA-based poxvirus vaccines remains concentrated among a single non-U.S. manufacturer, creating potential constraints during periods of heightened demand. Expanding manufacturing capacity and strengthening supply diversity may play an important role in future health security efforts.

GeoVax’s development portfolio is anchored by GEO-MVA, an MVA-based poxvirus vaccine candidate being advanced for protection against mpox and smallpox and intended to support a more diversified global poxvirus vaccine supply. GeoVax is also advancing Gedeptin^®, an immuno-oncology program designed to enhance anti-tumor immune responses in solid tumors. The Company’s broader technology portfolio includes preclinical vaccine candidates targeting hemorrhagic fever pathogens, including Ebola and Marburg viruses, which have demonstrated encouraging efficacy in animal studies and may provide future strategic optionality for biodefense and global health applications.

“As the world comes together to celebrate FIFA World Cup 2026, we extend our congratulations to the athletes who have dedicated years to reaching this global stage and to the organizers responsible for bringing this remarkable event to life,” concluded Dodd. “The success of gatherings like these depends not only on what happens on the field, but also on the public health systems, healthcare infrastructure, and operational planning that support them behind the scenes. By investing in manufacturing capacity, disease surveillance, and biodefense capabilities today, we can help ensure that the world’s attention remains focused where it belongs – on the athletes, the competition, and the spirit of international cooperation.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin^®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected]

Release – Nicola Mining To Commence Gold Production At Dominion Gold Project

Posted on June 1, 2026June 1, 2026 by [email protected]

Research News and Market Data on NICM

June 1, 2026

VANCOUVER, B.C., June 1, 2026 – Nicola Mining Inc. (NASDAQ: NICM) (TSXV: NIM) (FSE: HLIA), (the “Company” or “Nicola”) is pleased to announce that it is in the final stages of preparation to commence gold and silver extraction operations at its Dominion Gold Project (“Dominion”). The high-grade gold project is located approximately 43 kilometres northeast of the Town of Wells and 110 kilometres southeast of Prince George, British Columbia. Material extracted from Dominion will be processed at the Company’s wholly owned Merritt Mill, the only fully permitted milling facility in British Columbia authorized to process gold and silver material sourced from throughout the province.

In anticipation of commencement of operations, the Company has advanced multiple key infrastructure, equipment, and operational initiatives, while also strengthening its reclamation profile through an additional $251,000 payment toward reclamation bonding requirements under Mines Act Permit MX-100000488^[1], as well as the following:

Completion of the final payment for the purchase and installation of a fully furnished 14-person operational camp, including all required site facilities^[2];
Acquisition of three CATERPILLAR 336-07 excavators;
Acquisition of Traxxon TR-EX2000 High Performance Rock Drill attachment;
Securing of a John Deere 310E haul truck;
Hiring of operational crews and engagement of key mining contractor

Mill feed extraction is expected to commence first week of July.

Mr. Peter Espig, CEO of Nicola Mining Inc., commented:

“Dominion represents a highly compelling high-grade gold asset that we believe possesses both exceptional near-term production potential and significant long-term strategic value for Nicola. The project has consistently demonstrated robust mineralization, with vein systems remaining open in all directions and returning grades of up to 113 grams of gold per tonne (3.31 ounces of gold per tonne)^[3]. As we transition toward extraction, we are particularly excited by the opportunity to establish Dominion as a meaningful and sustainable source of premium-grade mill feed for our Merritt Mill operations. Concurrently, we continue to work closely with Blue Lagoon Resources Inc., which continues to achieve important production milestones while maintaining strong operational discipline and grade control. We believe the convergence of these developments positions Nicola for a transformative period of operational growth and increasing cash flow generation.”

Qualified Person

The scientific and technical disclosures included in this news release have been reviewed and approved by Will Whitty, P.Geo., who is the Qualified Person as defined by NI 43-101. Mr. Whitty is Vice President of Exploration for the Company.

DOMINION CREEK PROPERTY HISTORY

The Dominion Creek Property consists of 9 mineral claims (55 units) totaling approximately 1,058 hectares. The property was acquired from the prospector N. Kencayd by Noranda Exploration Company Ltd. in 1986. Noranda subsequently conducted geological, geochemical, and geophysical surveys which culminated in an increase in their land position. Between 1987 and 1990, Noranda’s exploration program included a small (20 samples) geochemical silt sample survey. Encouraged by those results, a larger soil geochemical survey (3,399 samples) was conducted. Noranda drilled a total of 53 shallow diamond drill holes, totaling 3,483.86 meters (average depth of approximately 65.7 meters). Trenching of several coincident Pb, Zn, Cu, Ag and Au soil geochemistry anomalies resulted in the discovery of several mineralized quartz veins.

A Technical Report^[4] on the Dominion Creek Project was completed by Geospectrum Engineering on August 22, 2003.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the NASDAQ, the TSX Venture Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia. It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig”
Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Nicola had already paid $137,000

[2] July 30, 2025, news release: Link

[3] November 10, 2025, news release: Link

[4] Makepeace, D. K., 2003. Dominion Creek Project Technical Report for XMP Mining Ltd. Geospectrum Engineering, August 22.

Release – Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Posted on June 1, 2026 by [email protected]

Research News and Market Data on GLSI

Download as PDFJune 01, 2026 6:00am EDT

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

The Form 10-K for the fiscal year ending December 31, 2025, continues to be audited by our new auditor and we believe it is in the final approval steps. The Form 10-K also includes the 2024 audit that was previously audited by the prior auditor. As previously indicated, the accounts payable adjustments are related to the large global Phase III clinical trial underway and the unexpectedly large increase in screening and patient enrollment in Europe in 2024 and 2025. Both auditors in a dual auditor filing must agree in order to make timely filings, which did not occur in March or April, and such coordination is still required as part of the final approval steps.

The Company believes that it did not contribute to the delays in filing and instead did everything possible to file on time. The Company provided the 10K filing information with large increases to accounts payable to the auditors for review in early February 2026 and requested and anticipated an early filing. The Company has further improved its accounts payable estimations using current clinical trial data in its financials for Form 10-Q for the period ending March 31, 2026.

The Company believes that the accounts payable adjustments are not material to the Company or its investors and does not change the fundamentals of the Company. The shift in expenses does not change the cash balance or the net cash used in operating activities of the Company. As previously announced, the Company’s ending cash balance as of March 31, 2026 is approximately $10.5 million, which the Company believes is an improvement over 2025 ending cash balances, and includes the retirement of over 75% of accounts payable for the fiscal year ending December 31, 2025. This $10.5 million cash balance is more than the 2025 net cash used in operating activities which is approximately $9.9 million. The above figures are unaudited and are subject to change following the completion of the Company’s financial audit for the year ending December 31, 2025 and the review for the period ending March 31, 2026.

About FLAMINGO-01 Open Label Phase III Data

More than 1,300 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
- The AACR Meeting 2026 delayed-type-hypersensitivity (DTH) poster can be downloaded here.
- The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, p < 0.001).
- As reported in Table 1 of the poster, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline with frequency increasing from 100% to 700%.
- Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100. Baseline immune response to GP2 prior to any vaccination with GP2 was also observed in the Phase IIb trial and is being observed in the blinded randomized arms of FLAMINGO-01, where HLA-A*02 only patients are being vaccinated.

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:

80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Source: Greenwich LifeSciences, Inc.

Released June 1, 2026

Release – MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

Posted on June 1, 2026June 1, 2026 by [email protected]

Research News and Market Data on MAIA

June 01, 2026 8:00am EDT Download as PDF

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, delivered a poster presentation on May 31, 2026, featuring the methodology and study design for its pivotal Phase 3 clinical trial (THIO-104) at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO 2026), being held May 29 – June 2, 2026, in MAIA’s home city of Chicago, Illinois. THIO-104 evaluates the efficacy of MAIA’s telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients resistant to CPIs and chemotherapy. MAIA reported the first patient dosed in THIO-104 in December 2025, and screening and enrollment is underway in Europe and Asia.

“We’re pleased to be back at ASCO, where many of the world’s leading oncology experts gather to discuss the latest advances shaping the future of cancer treatment,” said MAIA CEO Vlad Vitoc, M.D. “The level of engagement and enthusiasm surrounding our clinical programs is very encouraging, particularly as investigators continue enrolling patients in both our pivotal Phase 3 THIO-104 trial and Phase 2 THIO-101 trial expansion.”

MAIA’s ASCO 2060 poster, titled “A Phase 3 Study of Ateganosine (THIO) Sequenced with Immune Checkpoint Inhibitor (ICI) versus Standard of Care Chemotherapy in ICI-Resistant Advanced NSCLC: THIO-104 Trial in Progress,” was presented by Tomasz Jankowski, M.D., Phase 2 THIO-101 lead investigator for Poland, enrollment advisor for the pivotal Phase 3 THIO-104 clinical trial and co-author of several MAIA scientific presentations. The poster is attached to this press release and is also available on the Publications page of MAIA’s website maiabiotech.com.

“Investigators are increasingly focused on therapies that can potentially overcome resistance mechanisms and improve outcomes for patients with advanced NSCLC,” said Dr. Jankowski.

“Ateganosine has generated meaningful interest within the oncology community and may offer a promising new therapeutic option for patients who currently face very limited treatment choices.”

The ASCO Annual Meeting is the world’s largest cancer research meeting, with nearly 45,000 attendees and 166 countries represented in 2025.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-104 Phase 3 Clinical Trial

THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

Attachment

MAIA ASCO 2026 -THIO-104 TIP

Source: MAIA Biotechnology, Inc.

Released June 1, 2026